Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

NCT03960840 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

217

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Diffuse Large B-cell Lymphoma
Acute Lymphoblastic Leukemia
Large B-cell Lymphoma

Interventions

BIOLOGICAL: Rapcabtagene autoleucel single agent
DRUG: Ibrutinib

Sponsor

Novartis Pharmaceuticals